Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127863 | 0.87 | CHRM5 (0.48) | MEN1KMT2AKDM4EADRA1AOPRM1 | |
| SCHEMBL5121405 | 0.76 | SIGMAR1 (0.42) | MEN1KMT2AKDM4EMAPK1MCHR1 | |
| SCHEMBL5117815 | 0.71 | CHRM3 (0.45) | MEN1KMT2AKDM4EMAPK1ADRA1D | |
| SCHEMBL5117812 | 0.71 | CHRM3 (0.45) | MEN1KMT2AKDM4EMAPK1ADRA1D | |
| SCHEMBL6802893 | 0.70 | HRH3 (0.50) | MEN1KMT2AKDM4EMAPK1ADRA1D | |
| SCHEMBL5121398 | 0.69 | KMT2A (0.43) | MEN1KMT2AKDM4EMAPK1ADRA1D | |
| SCHEMBL6270367 | 0.69 | ALDH1A1 (0.47) | MEN1KMT2AKDM4EMAPK1ADRA1D | |
| SCHEMBL5918372 | 0.69 | ADRA1D (0.46) | MEN1KMT2AKDM4EMAPK1ADRA1D | |
| SCHEMBL5918375 | 0.69 | ADRA1D (0.46) | MEN1KMT2AKDM4EMAPK1ADRA1D | |
| SCHEMBL4391727 | 0.69 | ALDH1A1 (0.49) | MEN1KMT2AKDM4EMAPK1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465751-B2 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | CHRM3, CHRM1, CHRM5 | MEN1 1478/4885KMT2A 3693/4885KDM4E 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.